Piper Jaffray analyst Charles C. Duncan reiterated an Overweight rating and boosted his price target on ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Leerink Partners Raises Price target on Neurocrine Biosciences (NBIX) Following Positive KINECT3 Results October 8, 2015 2:49 PM Neurocrine Bio. (NBIX) PT Bumped to $66 at Baird on NBI-98854 Phase 3 SuccessOctober 8, 2015 1:44 PM Neurocrine Bio. (NBIX) Bullish Stance Reiterated at CowenOctober 8, 2015 12:46 PM Neurocrine Biosciences (NBIX) Announces Significant Data from NBI-98854 Kinect 3 in Lardive DyskinesiaOctober 8, 2015 6:34 AM Neurocrine Announces Positive Results from Phase III Kinect 3 Study of NBI-98854 in Tardive DyskinesiaOctober 8, 2015 6:30 AM